Inclusion Criteria at the time of initial registration:

• Must have a histologically confirmed diagnosis of SCLC.
• Must have extensive stage SCLC and/or lesions that have spread to other tissues in the chest or other parts of the body.
• Must have completed first line chemotherapy: 4-6 cycles of a standard platinum/etoposide regimen.
• ECOG performance status of 0-2.

• Adequate organ function including:

  1. WBC > 3,000/mm³ and ANC > 1500/ mm³
  2. Platelets > 100,000/ mm³
  3. Hematocrit > 25%
  4. Hemoglobin ≥10g/dl
  5. Bilirubin < 2.0 mg/dl
  6. Creatinine < 2.0 mg/dl
  7. AST/SGOT ≤2 x ULN
  8. Alkaline phosphatase ≤3 x ULN
• Tumor Assessment: SD, PR, or CR assessed 3 weeks after the last cycle of first line chemotherapy
• Males and Females of reproductive potential must agree to use effective contraception during the study and for at least 4 weeks after the last dose of ATRA. Patients are instructed and agree to notify the principal investigator should a pregnancy occur for themselves or their partner.
• Must be willing and able to sign written informed consent and be able to comply with the study protocol for the duration of the study.

Inclusion Criteria just prior to treatment with vaccines:

• Must have had a successful harvest of PBMC with leukapheresis at least 6 weeks after chemotherapy.
• ECOG performance status must be 0-2.
• The last dose of first line chemotherapy must have been administered at least 4 weeks prior to the first vaccine administration.
• For patients who received radiation therapy, the last dose of radiation must have been completed at least 4 weeks prior to the first vaccine administration and the patient must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia).
• For patients who received steroid therapy, the last steroid dose must have been given at least 4 weeks prior to the first vaccine administration

• Adequate organ function:

  1. WBC > 3,000/mm³ and ANC > 1500/ mm³
  2. Platelets > 100,000/ mm³
  3. Hematocrit > 25%
  4. Hemoglobin ≥10g/dl
  5. Bilirubin < 2.0 mg/dl
  6. Creatinine < 2.0 mg/dl
  7. AST/SGOT ≤ 2 x ULN
  8. Alkaline phosphatase < 3 x ULN
• Patients must have signed informed consent at initial registration.
• HLA-A*0201 Testing as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen, however this result will not be an inclusion criterion

Exclusion Criteria at the time of initial registration:

• Severe, uncontrolled intercurrent illness or infection.
• Anticipated requirement for chronic steroid use at the time of vaccination.
• Any pre-existing immunodeficiency condition, or a known history of HIV, Hepatitis B or Hepatitis C.
• Uncontrolled CNS metastasis will not be permitted.
• Pregnant or lactating women. A pregnancy test-serum BHCG will be obtained during the screening process.
• Patients who have received any chemotherapy other than the first line chemotherapy specified in the study protocol: standard platinum/etoposide regimen.
• Patients who have received any prior investigational drugs including immunotherapy, gene therapy, hormone therapy, biologic therapy for treatment of SCLC.
• Any known pre-existing autoimmune disorder.
• History of a second malignancy within the previous 5 years (except non-melanoma skin cancer and cervical in-situ).
• Patients who have not recovered from any chemotherapy-related or other therapy-related toxicity at study entry.
• Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment.
• Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study

Exclusion Criteria for vaccine registration:

• Uncontrolled brain metastasis.
• Ongoing steroid use or the anticipated requirement for steroid use during the treatment period.
• ECOG performance status of 3 or 4.
• Any serious ongoing infection.
• Patients who have had major surgery within 3 weeks of the start of vaccine treatment.